Nivolumab plus AVD is now FDA-approved for previously untreated Stage III or IV classical Hodgkin lymphoma in patients aged 12 years and older.

Dr. Bill Salter, senior director of radiation oncology at the Huntsman Cancer Institute, gives a tour of the treatment room at the Sen. Orrin G. Hatch Center for Proton Therapy at the institute in ...

Stage 3 Hodgkin’s lymphoma either indicates lymphoma in the lymph nodes both above and below a person’s diaphragm or in the lymph nodes above the diaphragm and in the spleen. Doctors may also refer to ...

In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es Salaam, Tanzania have shown that a ...

The U.S. Food and Drug Administration (FDA) on Friday approved Bristol Myers Squibb & Co.’s BMY Opdivo (nivolumab) with chemotherapy for untreated Hodgkin lymphoma, one of the most curable forms of ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

"We found that older age, early relapse, and noncurative treatments were significantly associated with inferior outcomes at a population level." — Inna Y. Gong, MD, PhD, hematologist in the Division ...

With the latest funding round, Blood Cancer United's cumulative research funding tops $2 billion, continuing to help increase survival rates and improve patients' lives Blood Cancer United's new ...

In a study published today in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of ...

Investigators analyzed OS and PFS for patients with follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/ prednisolone (CHOP ...

FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the supplemental application for nivolumab plus AVD. SWOG S1826 showed superior ...